← Leaderboards
William Gruber
Vanderbilt University
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Terence S. Dermody$49,981,852
- C. Henrique Serezani$10,097,790
- Isaac P Thomsen$3,654,672
- Pedro Enrique Cahn$5,497,954
- Harold L Moses$33,288,478
Others in their field
Top investigators on “Congenital Infection”
- Sallie R. Permar · Boston Children'S Hospital$17,196,768
- Jean-Laurent Casanova · Rockefeller University$16,451,858
- Barbara Driver · Westat, Inc.$16,395,100
- Rudolf P Bohm · Tulane University Of Louisiana$16,355,747
- David A Stoltz · University Of Iowa$15,578,422
- William J Britt · University Of Alabama At Birmingham$15,254,829
Research focus
Congenital InfectionNewborn Human (0-6 Weeks)Microorganism Disease ChemotherapyHuman Therapy EvaluationCongenital Nervous System DisorderCytomegalovirusDrug Screening /EvaluationEye InfectionsGanciclovirHerpes Simplex DiseaseHerpesviridae DiseaseHuman SubjectInfant Human (0-1 Year)Nervous System InfectionNeuropsychological TestsOral AdministrationOral Pharyngeal DisorderPolymerase Chain ReactionPreschool Child (1-5)Skin InfectionAcyclovirUrinalysisCerebrospinal FluidClinical Research
Grant awards (10)
EVALUATION OF SUPPRESSIVE THERAPY WITH ORAL ACYCLOVIR SUSPENSION$0
M01 · FY2002 · RR
GANCICLOVIR FOR TREATMENT OF SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2002 · RR
GANCICLOVIR FOR TREATMENT OF SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2001 · RR
GANCICLOVIR FOR TREATMENT OF SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2001 · RR
EVALUATION OF SUPPRESSIVE THERAPY WITH ORAL ACYCLOVIR SUSPENSION$0
M01 · FY2001 · RR
EVALUATION OF SUPPRESSIVE THERAPY WITH ORAL ACYCLOVIR SUSPENSION$0
M01 · FY2001 · RR
GANCICLOVIR FOR TREATMENT OF SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2001 · RR
EVALUATION OF SUPPRESSIVE THERAPY WITH ORAL ACYCLOVIR SUSPENSION$0
M01 · FY2001 · RR
GANCICLOVIR FOR TREATMENT OF SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONS$0
M01 · FY2000 · RR
EVALUATION OF SUPPRESSIVE THERAPY WITH ORAL ACYCLOVIR SUSPENSION$0
M01 · FY2000 · RR